Estimation of Some Biomarkers in Recovered COVID19 Patients

Abeer Ghazi  Nazzal; Ahmed Ghazi  Sabbar

doi:10.51173/jt.v4i33.587

Authors

Abeer Ghazi Nazzal College of Health & Medical Technology - Baghdad, Middle Technical University, Baghdad, Iraq
Ahmed Ghazi Sabbar College of Health & Medical Technology - Baghdad, Middle Technical University, Baghdad, Iraq

DOI:

https://doi.org/10.51173/jt.v4i33.587

Keywords:

Corona virus19, AST, IL-24, Sreumcreatinine

Abstract

A novel pandemic COVID-19 occurred in 2019. Most studies across the world are concerned with this outbreak. In this prospective study, a certain biomarker was estimated as a predicting factor in 150 recovered COVID-19 patients and group of 50 healthy controls. The serum creatinine, Aspartate aminotransferase, Interlukin-24, prothrombin time, and fibrinogen were measured using different techniques. The results revealed that the level of AST in recovered patients exceeded that of the healthy control group with a highly significant difference. There was also a highly significant increase in the level of IL-24 in recovered patients in comparison with that in healthy control, while both prothrombin time and fibrinogen levels were lower in recovered patients compared to healthy control. We conclude that the variation in the level of parameters of interest may reflect a prognostic view in recovered COVID-19 patients.

Downloads

Download data is not yet available.

References

Liu, T., et al., The role of interleukin‐6 in monitoring severe case of coronavirus disease 2019. EMBO molecular medicine, 2020. 12(7): p. e12421.

Cox, R.J. and K.A. Brokstad, Not just antibodies: B cells and T cells mediate immunity to COVID-19. Nature Reviews Immunology, 2020. 20(10): p. 581-582.

Swelum, A.A., et al., COVID-19 in human, animal, and environment: a review. Frontiers in Veterinary Science, 2020. 7: p. 578.

Perlman, S. and J. Netland, Coronaviruses post-SARS: update on replication and pathogenesis. Nature reviews microbiology, 2009. 7(6): p. 439-450.

Yin, Y. and R.G. Wunderink, MERS, SARS and other coronaviruses as causes of pneumonia. Respirology, 2018. 23(2): p. 130-137.

Wang, F., et al., Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. The Journal of infectious diseases, 2020. 221(11): p. 1762-1769.

Özdemir, Ö., Coronavirus Disease 2019 (COVID-19): Diagnosis and Management. Erciyes Medical Journal/Erciyes Tip Dergisi, 2020. 42(3).

Chovelon, B. and J. Arnaud, Influence of temperature of transport of whole blood on plasma Cu, I, Mn, Se and Zn and Mg concentrations in erythrocytes. Clinical Chemistry and Laboratory Medicine (CCLM), 2019. 57(6): p. e131-e133.

Jurado, A., et al., COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study. Immunity & Ageing, 2020. 17(1): p. 1-15.

Goshayeshi, L., et al., Demographic and clinical characteristics of severe Covid-19 infections: a cross-sectional study from Mashhad University of Medical Sciences, Iran. BMC infectious diseases, 2021. 21(1): p. 1-8.

Deng, Y., et al., Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. Chinese medical journal, 2020. 133(11): p. 1261-1267.

Patel, S., et al., Plasma ACE2 activity is increased in patients recovered from SARS-CoV-2 infection: Implications for the prolonged consequences oF COVID-19. Journal of Hypertension, 2021. 39: p. e394.

Wang, T., et al., Comorbidities and multi-organ injuries in the treatment of COVID-19. The Lancet, 2020. 395(10228): p. e52.

Gameil, M.A., et al., Long-term clinical and biochemical residue after COVID-19 recovery. Egyptian Liver Journal, 2021. 11(1): p. 1-8.

An, Y.-W., et al., Liver function recovery of COVID-19 patients after discharge, a follow-up study. International journal of medical sciences, 2021. 18(1): p. 176.

Song, Y., et al., Dynamic monitoring of immune function indexes in COVID-19 patients. Aging (Albany NY), 2020. 12(24): p. 24596.

Suljić, A., et al. Machine Learning Techniques for Prediction of Liver Fibrosis Based on Biomarkers. in International Conference on Medical and Biological Engineering. 2021. Springer.

Zhang, C., L. Shi, and F.-S. Wang, Liver injury in COVID-19: management and challenges. The lancet Gastroenterology & hepatology, 2020. 5(5): p. 428-430.

Feng, G., et al., COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. Journal of clinical and translational hepatology, 2020. 8(1): p. 18.

Chai, X., et al., Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. biorxiv, 2020.

Kirkwood, K. L. (2018). Inflammaging. In Immunological investigations (Vol. 47, Issue 8, pp. 770–773). Taylor & Francis.

Ren, X., Wen, W., Fan, X., Hou, W., Su, B., Cai, P., Li, J., Liu, Y.,Tang, F., & Zhang, F. (2021). COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell, 184(7), 1895–1913.

Wilk, A. J., Rustagi, A., Zhao, N. Q., Roque, J., Martínez-Colón, G.J., McKechnie, J. L., Ivison, G. T., Ranganath, T., Vergara, R., &Hollis, T. (2020). A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nature Medicine,26(7), 1 070–1076.

Mitamura, Y., Nunomura, S., Furue, M., & Izuhara, K. (2020). IL-24: A new player in the pathogenesis of pro-inflammatory and allergic skin diseases. Allergology International, 69(3), 405–411.

Chowdhury, A. T. M. M., Karim, M. R., Ali, M., Islam, J., Li, Y., &He, S. (2021). Clinical characteristics and the long term postrecovery manifestations of the COVID-19 patients-A prospective multicenter cross-sectional study. Frontiers in Medicine, 8, 1104.

Liao, D., Zhou, F., Luo, L., Xu, M., Wang, H., Xia, J., Gao, Y., Cai,L., Wang, Z., & Yin, P. (2020). Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. The Lancet Haematology, 7(9), e671–e678.

Xu, J., Zhang, Y., Li, Y., Liao, K., Zeng, X., Zeng, X., Meng, R.,Zhou, W., Wang, K., & Gong, Y. (2021). Dynamic Changes inCoagulation Function in Patients With Pneumonia Under Admission and Non-admission Treatment. Frontiers in Medicine, 8, 623.

Manigandan, S., Wu, M.-T., Ponnusamy, V. K., Raghavendra, V.B., Pugazhendhi, A., & Brindhadevi, K. (2020). A systematic review on recent trends in transmission, diagnosis, prevention and imaging features of COVID-19. Process Biochemistry.

Iba, T., Levy, J. H., Levi, M., Connors, J. M., & Thachil, J. (2020). Coagulopathy of coronavirus disease 2019. Critical Care Medicine

Dieguez, M. R., Pérez, A. M., Berlanga, A. M. P., Moles, Z. M., &Pupo, A. P. (2015). Coagulation disorders in chronic liver disease. Correo Científico Médico de Holguín, 19(1), 98–118.

Simurda, T., Vilar, R., Zolkova, J., Ceznerova, E., Kolkova, Z., Loderer, D., Neerman-Arbez, M., Casini, A., Brunclikova, M., &Skornova, I. (2020). A novel nonsense mutation in FGB (c. 1421G>A; p. Trp474Ter) in the beta chain of fibrinogen causing hypofibrinogenemia with bleeding phenotype. Biomedicines, 8(12), 605.

Arenas, R., Fernandez Martinez, R. F., Torres-Guerrero, E., &Garcia, C. (2017). Actinomycetoma: an update on diagnosis and treatment. Cutis, 99(2), E11-15.

Endemann, D. H., & Schiffrin, E. L. (2004). Endothelial dysfunction. Journal of the American Society of Nephrology, 15(8), 1983–1992.